Bio-Path Holdings, Inc.
BPTH- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001133818
No open-market purchases or sales by Bio-Path Holdings, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Q1 2024 vs. Q4 2023
How the institutions holding Bio-Path Holdings, Inc. changed between Q4 2023 and Q1 2024.
All holders in Q1 2024All holders in Q4 2023
| Measure | Q4 2023 | Q1 2024 | Change |
|---|---|---|---|
| Holders | 19 | 10 | −9 |
| SharesConverted for a 1-for-20 split | 29.9K | 19.1K | −10.8K (−36.1%) |
| Value | $276.5K | $78.6K | −$197.9K (−71.6%) |
New holders (0)
Institutions that held Bio-Path Holdings, Inc. at the end of Q1 2024 but not at the end of Q4 2023.
None.
Sold out (9)
Institutions that held Bio-Path Holdings, Inc. at the end of Q4 2023 and filed for Q1 2024 without it.
| Institution | Shares, Q4 2023 | Value, Q4 2023 |
|---|---|---|
| Geode Capital Management, LLC | 110,438 | $51.1K |
| Strategic Advocates LLC | 35,119 | $16.3K |
| Citadel Advisors LLC | 24,195 | $11.2K |
| Northern Trust Corp | 17,711 | $8.20K |
| HRT Financial LP | 17,294 | $8.00K |
| XTX Topco Ltd | 15,400 | $7.13K |
| State Street Corp | 13,033 | $6.03K |
| Advisor Group Holdings, Inc. | 10 | $5 |
| Royal Bank of Canada | 20 | $0 |